The evidence base for HRT: what can we believe?

Climacteric

Volumn 20, Issue 2, 2017, Pages 91-96

  Langer, R D ^a,b  

^a Jackson Hole Center for Preventive Medicine   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; coronary heart disease; Hormone replacement therapy; menopause; osteoporosis

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; CLINICAL TRIAL (TOPIC); FEMALE; HEART DEATH; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; MIDDLE AGED; RISK ASSESSMENT; WOMEN'S HEALTH;

CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 85014752763     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697137.2017.1280251     Document Type: Review

References (33)

1. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–9
2. Petitti DB, Perlman JA, Sidney S., Noncontraceptive estrogens and mortality:long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289–93
3. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women:results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–9
4. Paganini-Hill A, Ross RK, Henderson BE., Postmenopausal oestrogen treatment and stroke:a prospective study. BMJ 1988;297:519–22
5. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestin replacement. Br J Obstet Gynaecol 1992;99:821–8
6. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
7. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women:the Postmenopausal Estrogen/progestin Interventions (PEPI) trial. JAMA 1995;273:199–208
8. The Women’s Health Initiative Study Group. Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109
9. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
10. Thaul S, Hotra D, eds. An Assessment of the NIH Women’s Health Initiative. Committee to Review the NIH Women’s Health Initiative. Institute of Medicine, 1993
11. Women’s Health Initiative. Volume 1, Section 1–Protocol, Pages 1–17. 1994. Available from:https://web.njit.edu/∼wguo/Math654_2013/WHI_protocol.pdf
12. Women’s Health Initiative. Volume 1, Section 10–Protocol. 1994. Available from:https://web.njit.edu/∼wguo/Math654_2013/WHI_protocol.pdf
13. Anderson G, Kooperberg C, Geller N, et al. Monitoring and reporting of the Women’s Health Initiative randomized hormone therapy trials. Clin Trials 2007;4:207–17
14. National Institutes of Health. NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit. Press release, July 9, 2002. Available from:http://www.nhlbi.nih.gov/whi/pr_02-7-9.pdf [last accessed 29 Oct 16]
15. Women’s Health Initiative. Volume 1, Section 1–Protocol, Pages 1–54. 1994. Available from:https://web.njit.edu/∼wguo/Math654_2013/WHI_protocol.pdf
16. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
17. Women’s Health Initiative ‘HRT Update’, July 2002. Author’s archives
18. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
19. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer:the Women’s Health Initiative randomized controlled dietary modification trial. JAMA 2006;295:629–42
20. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy:the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
21. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
22. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease:the Women’s Health Initiative. Arch Intern Med 2006;166:357–65
23. Manson JE, Allison MA, Rossouw JE, WHI and WHI-CACS Investigators, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591–602
24. Women’s Health Initiative. Volume 1, Section 1–Protocol, Pages 1–15. 1994. Available from:https://web.njit.edu/∼wguo/Math654_2013/WHI_protocol.pdf
25. Rossouw JE, Prentice RL, Manson JE., Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
26. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
27. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women:randomised trial. BMJ 2012;345:e6409
28. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
29. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
30. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density:the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–38
31. Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy:results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
32. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
33. Baber RJ, Panay N, Fenton A, for the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50